



# Sanjaya Mendis

## Partner

Toronto

[smendis@mccarthy.ca](mailto:smendis@mccarthy.ca)

t. +1 416-601-7614

## Bar Admission

Ontario 2012

## Law School

University of Ottawa

## Practices

Mergers & Acquisitions

IP Litigation

Intellectual Property

## Industries

Life Sciences

Pharmaceutical

Sanjaya Mendis is a lawyer in our Intellectual Property Group in Toronto. Sanjaya is a trusted adviser to many of the world's largest innovative technology, pharmaceutical, and biotechnology companies on their litigation, regulatory, and commercial issues.

Sanjaya's civil litigation practice focuses on a variety of areas, including patent and trade-mark litigation, product liability and corporation/commercial law. Sanjaya provides strategic advice on regulatory matters relating to privacy, competition law, advertising, market access, product pricing, and anti-spam compliance issues.

Sanjaya has appeared as counsel in Ontario, the Federal Court, the Federal Court of Appeal, and the Supreme Court of Canada.

Sanjaya received his Bachelor of Science, Honours Specialization in Biochemistry, from the University of Ottawa in 2008. He also received his JD from the University of Ottawa's Faculty of Law in 2011. While attending law school, Sanjaya studied International and European Law for a semester at Université Jean Moulin (Lyon III).

In his spare time, Sanjaya is a volunteer with Pro Bono Ontario, and the University of Toronto's Downtown Criminal Legal Services clinic. Sanjaya is an avid outdoor sports enthusiast, having recently gone canyoneering in the Philippines, shark diving in South Africa, and surfing in Nicaragua.

## Awards & Rankings

### Managing Intellectual Property: IP Stars

Rising Star

### The Advocates' Society - 2020

Young Advocates' Standing Committee Civility Award Nominee

# Sanjaya Mendis

Partner

Toronto

[smendis@mccarthy.ca](mailto:smendis@mccarthy.ca)

t. +1 416-601-7614

## Recent Experience

- **Apple and WiLAN settle mobile handover patent dispute in Canada**

March 22, 2022

## Recent Insights

- **Apotex's Section 8 Damages Claim for Atomoxetine Denied under the PM(NOC) Regulations**

May 3, 2023

- **FCA Clarifies Law on Induced Infringement for Generic/Biosimilar Drugs**

April 17, 2023

- **Ontario Court of Appeal Dismisses Apotex's Novel Patent Damages Appeal**

August 19, 2022

- **AI and Patent Law: Can AI Be an "Inventor"?**

May 31, 2022

